Core Viewpoint - Viemed Healthcare is upgraded to a 'Buy' rating following a strong Q2 earnings report and positive technical indicators, despite previous concerns about growth and market trends [2][3]. Technical Analysis - A bullish crossover of the MACD indicator suggests a potential upward trend for Viemed's stock, indicating favorable conditions for price appreciation [3]. - The stock has recently broken above a bearish trend line, and while it faces resistance at the 200-day moving average of approximately $7.78, there is optimism for overcoming this barrier [6]. - Strong buying volume has been observed despite a 27% decline from March highs of approximately $10, indicating potential for a price rebound [6][7]. Encouraging Q2 Trends - Viemed reported record revenue of $55 million in Q2, reflecting a 27% rolling quarter growth and an increase in active ventilator patients by 4.4% [8]. - The restructuring of the sales team has led to improved performance and increased reach to patients, suggesting a scalable growth model for the company's ventilator business [9]. - The introduction of GLP1 drugs has not negatively impacted Viemed's sleep business; instead, it has heightened awareness and sustained growth in CPAP and sleep product lines [10]. Strategic Opportunities - The recall of Philips' ventilators presents a unique opportunity for Viemed to upgrade its fleet through a buy-back agreement, allowing for the replacement of older units without negatively impacting cash flows [11]. - The company is leveraging volume purchase discounts to enhance its inventory while reducing servicing costs associated with older machines [11]. Valuation Perspective - Viemed's trailing GAAP multiple of nearly 32 may seem high, but its sales and book multiples are significantly below 5-year averages, indicating attractive valuation for potential earnings growth [12]. - The company's trailing price-to-sales ratio is 1.37, which is 45.9% lower than its 5-year average, and the price-to-book ratio is 2.38, 40.3% below its historical average [12]. Conclusion - Continued investments in technology, particularly the Engage platform, alongside positive technical indicators and growing patient counts, suggest a favorable outlook for Viemed's share price in the near term [13].

Financial Data and Key Metrics Changes - The company achieved a record net revenue of $55 million in Q2 2024, representing a 27% increase compared to $43.3 million in Q2 2023 [4][12] - Gross margin for the quarter was 60%, while EBITDA margin was 23%, with gross and EBITDA amounts at $32.9 million and $12.8 million respectively [13] - SG&A expenses totaled approximately $26.5 million, up from $20.6 million in Q2 2023, but G&A as a percentage of revenue decreased sequentially from 49% in Q1 to 48% in Q2 2024 [14] Business Line Data and Key Metrics Changes - Revenue from ventilators accounted for approximately 56% of total revenue, down from 60% in Q2 2023 [13] - The sleep business now represents 15% of total revenue, experiencing strong organic growth driven by increased health awareness [9] - New ventilator setups grew by 4.4% during the quarter, with a 15% increase in average monthly setups per sales rep compared to the beginning of the year [5][6] Market Data and Key Metrics Changes - Market penetration for noninvasive ventilation remains below 10%, indicating significant growth potential [7] - The company is actively engaging in research to educate payers on the benefits of noninvasive ventilation, which may enhance market acceptance [7] Company Strategy and Development Direction - The company is focused on organic growth as the highest priority, with plans for inorganic growth and debt paydown as secondary priorities [17] - The recent acquisition of East Alabama HomeMed is expected to create further growth opportunities and enhance operational efficiencies [4][12] - The company is leveraging the Philips recall to replace aging ventilators, which is anticipated to improve operational efficiency and reduce costs [8][25] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about continued high organic growth rates and the successful integration of acquisitions [13][19] - The company is confident in its ability to navigate regulatory challenges and capitalize on market opportunities, particularly in the noninvasive ventilation sector [19][37] - Future revenue guidance for Q3 2024 is set between $56.5 million and $57.7 million, reflecting a 16% increase over the same period in 2023 [18] Other Important Information - The company has successfully migrated all payers away from Change Healthcare, mitigating potential impacts from a cyber attack [10] - The company is actively pursuing mergers and acquisitions in the home healthcare sector, indicating a robust M&A pipeline [12] Q&A Session Summary Question: How does the company prioritize opportunities in a target-rich environment? - Management aims to be efficient and strategic in pursuing opportunities, focusing on maximizing production through improved training and management [21][22] Question: Are there opportunities to replicate the recent joint venture structure in other markets? - Management is in the process of proving the model with the current joint venture and expects to leverage this success for future opportunities [24] Question: How does the Philips recall impact the company? - The recall allows the company to sell back older equipment and reinvest in new devices, creating a favorable cost situation and operational gains [25] Question: What is the contribution of the sleep resupply program to revenue? - The sleep resupply program is a significant driver of long-term value, with expectations for continued growth as more patients are added [29] Question: Is there seasonality in service revenue? - There is no significant seasonality expected in service revenue, which is driven by the healthcare staffing division [30] Question: How is the company addressing the impact of GLP-1 drugs on the sleep business? - The sleep business remains strong, with no significant attrition or service drop-off observed [33] Question: What are the expectations for M&A pricing in the current market? - Public multiples are expected to stabilize, and the company remains prudent in evaluating potential acquisitions [35] Question: What is the outlook for the noninvasive ventilation market? - The market is still underserved, and ongoing research is expected to drive higher penetration rates in the future [37]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Title of each class Trading Symbol(s) Name of exchange on which registered Common Shares, no par value VMD The Nasdaq Stock Market LLC ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number: ...

VIEMED HEALTHCARE ANNOUNCES RECORD SECOND QUARTER 2024 FINANCIAL RESULTS Lafayette, Louisiana (August 7, 2024) Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its financial results for the three and six months ended June 30, 2024. Operational highlights (all dollar amounts are USD): • Net revenues for the quarter ended June 30, 2024 reached a new Company record ...

LAFAYETTE, La., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its financial results for the three and six months ended June 30, 2024. Operational highlights (all dollar amounts are USD): Net revenues for the quarter ended June 30, 2024 reached a new Company record of $55.0 million, representing an increase of $11.7 million, o ...

Interested parties may participate in the call by dialing: Financial professionals are invited to call in to register in advance to ask questions. To pre-register as a qualified caller, please e-mail investorinfo@viemed.com by 12:00 p.m. ET Wednesday, August 7, 2024. Following the live call, a replay will be available in the Investor Relations section of the Company's website, www.viemed.com. ABOUT VIEMED HEALTHCARE, INC. Viemed is a provider of in-home medical equipment and post-acute respiratory healthcar ...

LAFAYETTE, La., July 24, 2024 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it will host its Quarterly Conference Call on Thursday, August 8, 2024 at 11:00 a.m. ET. Financial professionals are invited to call in to register in advance to ask questions. To pre-register as a qualified caller, please e-mail investorinfo@viemed.com by 12:00 p.m. ET Wednesday, ...

Viemed Healthcare, Inc. (NASDAQ:VMD) Q1 2024 Earnings Conference Call May 7, 2024 11:00 AM ET Company Participants Todd Zehnder – COO Casey Hoyt - CEO Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Doug Cooper - Beacon Securities Alexander Graf - Riva Ridge capital Jeffrey Bronchick - Cove Street Capital Operator Greetings, and welcome to the Viemed First Quarter 2024 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to i ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number: 001-38973 Viemed Healthcare, Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada N/A (State or other ...

VIEMED HEALTHCARE ANNOUNCES FIRST QUARTER 2024 FINANCIAL RESULTS Lafayette, Louisiana (May 6, 2024) Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its financial results for the three months ended March 31, 2024. Operational highlights (all dollar amounts are USD): For further information, please contact: "I am tremendously enthusiastic about the Company's perf ...